

CERTIFICATE OF MAILING

09/9/01 81

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below.

| | | | | | |
|---|---|---------------------------|--------------------|-----------------------|------------------|
| Name (Print/Type) | Margaret Pierce | Signature | <i>M. Pierce</i> | Date | 21 09-20-2001 |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | Express Mail No.. | EL923478938US | | |
| | | Intl. Filing Date | March 22, 2000 | | |
| | | First Named Inventor | Geoffrey P. Dobson | | |
| | | Examiner | Unassigned | | |
| | | Group Art | Unassigned | | |
| | | Attorney Docket Number | FREE001 | | |
| International Application No. | PCT/AU00/00226 | International Filing Date | 03-22-2000 | Priority Date Claimed | 03-23-1999 |
| Title of Invention | Organ Arrest, Protection and Preservation | | | | |
| Applicant(s) for DO/EO/US | Geoffrey P. Dobson | | | | |

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9), (21) indicated below.
4. The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US). (Courtesy copy attached)
6. An English language translation of the International Application as filed (35 U.S.C. 37(c)(2)).
 - a. is attached hereto
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 37(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).


Items 11 to 20 below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A FIRST preliminary amendment.
14. A SECOND or SUBSEQUENT preliminary amendment.
15. A substitute specification.
16. A change of power of attorney and/or address letter.

J9/937181

17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825
 18. A second copy of the published international application under 35 U.S.C. 154(d)(4).
 19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
 20. Other items or information:

Return receipt postcard

| | | | |
|--|---------------------|----------------------------------|-------------|
| 21. <input checked="" type="checkbox"/> Fees | | CALCULATIONS PTO USE ONLY | |
| BASIC NATIONAL FEE (37 CFR 1.492(a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO..... | | \$1,000.00 | |
| International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Serach Report prepared by the EPO or JPO.... | | \$860.00 | |
| International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... | | \$710.00 | |
| International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... | | \$690.00 | |
| International preliminary examiniation fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... | | \$100.00 | |
| ENTER APPROPRIATE BASIC FEE AMOUNT | | = | \$ 1,000.00 |
| <input checked="" type="checkbox"/> Surcharge of \$130.00 for furnishing the oath or declaration later than 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). | | \$ | |
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE |
| Total Claims | 43 | 23 | \$18.00 |
| Independent Claims | 5 | 2 | \$80.00 |
| <input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS (if applicable) | | \$270.00 | \$ 270.00 |
| TOTAL OF ABOVE CALCULATIONS | | \$ 844.00 | |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. | | \$ 922.00 | |
| SUBTOTAL | | \$ 922.00 | |
| <input checked="" type="checkbox"/> Processing fee of \$130.00 for furnishing the English Translation later than 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). | | | |
| TOTAL NATIONAL FEE = | | \$ 922.00 | |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assigment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property. | | | |
| TOTAL FEES | | \$ 922.00 | |
| | | Amount to be refunded | \$ |
| | | charged: | \$ 922.00 |
| <input checked="" type="checkbox"/> The Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account 50-0815. If additional fees are required, including extensions of time, please consider this a petition therefore. A duplicate copy of this sheet is enclosed. | | | |
| NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. | | | |
| SEND ALL CORRESPONDENCE TO: BOZICEVIC, FIELD & FRANCIS, LLP 200 Middlefield Road, Suite 200 Menlo Park, California 94025 Telephone - Direct Dial 650-833-7774 Facsimile 650-327-3231 | | | |
|  SIGNATURE Carol M. LaSalle NAME 39,740 REGISTRATION NUMBER | | | |

Express Mail Label No. EL 824 073 208 US

| | | |
|----------------------------------|-----------------------------|---|
| PRELIMINARY AMENDMENT | Attorney Docket | FREE001 |
| | First Named Inventor | Geoffrey P. Dobson. |
| | Application Number | 09/937,181 |
| | Intl. Filing Date | March 22, 2000 |
| | Group Art Unit Conf. No. | To Be Assigned 6148 |
| | Examiner Name | To Be Assigned |
| | Title | Organ Arrest, Protection and Preservation |

Sir:

This is a preliminary amendment to the patent application identified above. Prior to examination of the subject application, please enter the following amendments to the claims:

AMENDMENTSIN THE CLAIMS:

Please cancel claims 9-43 without prejudice. Please amend claims 1-8 and add new claims 44-93 as follows.

1. (Amended) A method for arresting, protecting or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof.

2. (Amended) The method of claim 1, wherein the organ is either intact in the body of the subject or is isolated.

3. (Amended) The method of claim 1, wherein the organ is a circulatory organ, respiratory organ, urinary organ, digestive organ, reproductive organ, neurological organ or somatic cell.

4. (Amended) The method of claim 3, wherein the circulatory organ is a heart.

5. (Amended) The method of claim 4, which is used to arrest, protect or preserve the heart during open-heart surgery, reduce heart damage before, during or following cardiovascular intervention or protect those portions of the heart that have been starved of normal flow, nutrients or oxygen.

6. (Amended) The method of claim 1, wherein the potassium channel opener or agonist is selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy5(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benimidazol-one), amlodipine, Bay K 8644(L-type), (1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HCl (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIC (Q-type), cyproheptadine HC1, dantrolene sodium (Ca^{2+} release inhibitor), diltiazem HC1 (L-type), filodipine, flunarizine HC1 ($\text{Ca}^{2+}/\text{Na}^+$), fluspirilene (L-type), HA-1077 2HC1(1-(5 isoquinolinyl sulphonyl) homo piperazine.HCl), isradipine, loperamide HC1, manoalide (Ca^{2+} release inhibitor), nicardipine HC1 (L-type), nifedipine (L-type), niguldipine HC1 (L-type), nimodipine (L-type), nitrendipine (L-type), pimozone (L- and T- type), ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HC1 (L-type), methoxy-verapamil HC1 (L-type), YS-035 HC1 (L-type)N[2(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethaneamine HC1) and AV blockers.

7. (Amended) The method of claim 6, wherin the AV blocker is adenosine.

8. (Amended) The method of claim 1, wherein the adenosine receptor agonist is selected from N^6 -cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro- N^6 -cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N^6 -(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

Claims 9- 43 are cancelled.

44. (New) The method of claim 3, wherein the adenosine receptor agonist is selected from N^6 -cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro- N^6 -cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N^6 -(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

45. (New) The method of claim 4, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robocuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenine (CHA).

46. (New) The method of claim 5, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robocuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenine (CHA).

47. (New) The method of claim 6, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robocuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenine (CHA).

48. (New) The method of claim 7, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robocuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenine (CHA).

49. (New) The method of claim 8, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

50. (New) The method of claim 44, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

51. (New) The method of claim 45, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

52. (New) The method of claim 46, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

53. (New) The method of claim 47, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

54. (New) The method of claim 48, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

55. (New) The method of claim 49, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

56. (New) The method of claim 50, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

57. (New) The method of claim 1, wherein the local anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mipivacaine and Class 1B antiarrhythmic agents.

58. (New) The method of claim 51, wherein the class 1B antiarrhythmic agent is lignocaine.

59. (New) The method of claim 1, wherein active ingredients (i) and (ii) are administered together with a pharmaceutically acceptable carrier, diluent, adjuvant or excipient.

60. (New) The method of claim 53, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient is a buffer having a pH of about 6 to about 9.

61. (New) The method of claim 54, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient is a buffer having a pH of about 6 to about 9.

62. (New) The method of claim 54, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient has low concentrations of potassium.

63. (New) The method of claim 62, wherein the concentration of potassium is up to about 10mM.

64. (New) The method of claim 57, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

65. (New) The method of claim 60, wherein the buffer is Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Fremes solution, Hartmanns solution or Ringers-Lactate.

66. (New) The method of claim 59, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient has low concentrations of magnesium.

67. (New) The method of claim 66, wherein the concentration of magnesium is up to about 2.5 mM.

68. (New) The method of claim 1, wherein the active ingredients (i) and (ii) are administered together with another medicament.

69. (New) The method of claim 68, wherein the medicament is dipyridamole or a clot-busting drug.

70. (New) The method of claim 69, wherein the clot-busting drug is streptokinase.

71. (New) The method of claim 1, wherein the subject is a neonate/infant.

72. (New) The method of claim 4, wherein the administration in cardiovascular applications is achieved by mixing the active ingredients with the blood of the subject or a subject having a similar blood type.

73. (New) The method of claim 1, wherein the administration in cardiovascular applications is achieved by mixing the active ingredients with the blood of the subject or a subject having a similar blood type.

74. (New) The method of claim 1, wherein arrest is achieved by either continuous or intermittent delivery.

75. (New) The method of claim 1, wherein the arrest occurs at temperatures of about 15°C to about 37°C.

76. (New) A method for arresting, protecting or preserving an organ comprising adding a composition which includes effective amounts of (i) potassium channel opener or agonist or an

adenosine receptor agonist and (ii) a local anaesthetic for use in arresting, protecting or preserving an organ.

77. (New) A pharmaceutical or veterinary composition comprising effective amounts of (i) a potassium channel opener or agonist or an adenosine receptor agonist and (ii) a local anaesthetic.

78. (New) A composition as claimed in claim 77, wherein the potassium channel opener or agonist is selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy5(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benimidazol-one), amlodipine, Bay K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HC1 (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIIC (Q-type), cyproheptadine HC1, dantrolene sodium (Ca^{2+} release inhibitor), diltiazem HC1 (L-type), filodipine, flunarizine HC1 ($\text{Ca}^{2+}/\text{Na}^+$), fluspirilene (L-type), HA-1077 2HC1(1-(5 isoquinoliny1 sulphonyl) homo piperazine.HC1), isradipine, loperamide HC1, manoalide (Ca^{2+} release inhibitor), nicardipine HC1 (L-type), nifedipine (L-type), niguldipine HC1 (L-type), nimodipine (L-type), nitrendipine (L-type), pimozone (L- and T- type), ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HC1 (L-type), methoxy-verapamil HC1 (L-type)N[2(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethaneamine HC1) and AV blockers.

79. (New) The composition of claim 77, wherein the adenosine receptor agonist is selected from N^6 -cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro- N^6 -cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a, 2b, 3b, 4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579, N^6 -(R)-phenylisopropyladenosine (R-PLA), amnophenylethyladenosine 9APNEA) and cyclohexyladenosine (CHA).

80. (New) The composition of claim 77, wherein the local anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mipivacaine and Class 1B antiarrhythmic agents.

81. (New) The composition of claim 77, wherein the local anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mipivacaine and Class 1B antiarrhythmic agents.

82. (New) The composition of claim 77, wherein the composition is a cardioplegic or cardioprotectant composition.

83. (New) The composition of claim 77, wherein active ingredients (i) and (ii) are administered together with a pharmaceutically acceptable carrier, diluent, adjuvant or excipient.

84. (New) The composition of claim 83, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient, is a buffer having a pH of about 6 to about 9.

85. (New) The composition of claim 83, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient, has low concentrations of potassium.

86. (New) The composition of claim 85, wherein the concentration of potassium is up to about 10mM.

87. (New) The composition of claim 84, wherein the buffer is Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Femes solution, Hartmanns solution or Ringers-Lactate.

88. (New) The composition of claim 84, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient has low concentrations of magnesium.

89. (New) The composition of claim 88, wherein the concentration of magnesium is up to about 2. 5mM.

90. (New) The composition of claims 78 wherein the active ingredients (i) and (ii) are administered together with another medicament.

91. (New) The composition of claim 90, wherein the medicament is dipyridamole or a clot-busting drug.

92. (New) The composition of claim 91, wherein the clot-busting drug is streptokinase.

93. (New) The composition of claim 78, wherein the AV blocker is adenosine.

REMARKS UNDER 37 CFR § 1.111

Formal Matters

Claims 1-8 and 44-93 are pending after entry of the amendments set forth herein.

Claims 9-43 are hereby cancelled without prejudice with renewal, without intent to acquiesce to any rejection that may be applied thereon, and without the intent to abandon any subject matter encompassed therein.

Replace claims 1-8 with the clean version provided in the “clean copy”. The changes are shown in the attached “Version with Markings to Show Changes Made”.

New claims 44-93 are hereby added.

No new matter has been added.

Conclusion

Applicants submit that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

Atty Dkt. No.: FREE001
USSN: 09/937,181

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number FREE001.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 1/10/02

By: Carol M. LaSalle
Carol M. LaSalle
Registration No. 39,740

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please cancel claims 9-43 without prejudice. Please amend claims 1-8 and add new claims 44-93 as follows.

1. (Amended) A method for arresting, protecting [and/]or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist [and/]or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof.
2. (Amended) [A] The method [as claimed in] of claim 1, wherein the organ is either intact in the body of the subject or is isolated.
3. (Amended) [A] The method [as claimed in] of claim 1, wherein the organ is a circulatory organ, respiratory organ, urinary organ, digestive organ, reproductive organ, neurological organ or somatic cell.
4. (Amended) [A] The method [as claimed in] of claim 3, wherein the circulatory organ is a heart.
5. (Amended) [A] The method [as claimed in] of claim 4, which is used to arrest, protect [and/]or preserve the heart during open-heart surgery, reduce heart damage before, during or following cardiovascular intervention or protect those portions of the heart that have been starved of normal flow, nutrients [and/]or oxygen.
6. (Amended) [A] The method [as claimed in any one] of claim[s] 1 [to 5], wherein the potassium channel opener or agonist is selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy5(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benimidazol-one), amlodipine, Bay K 8644(L-type), (1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HCl (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIIC (Q-type),

cyproheptadine HC1, dantrolene sodium (Ca^{2+} release inhibitor), diltiazem HC1 (L-type), filodipine, flunarizine HC1 ($\text{Ca}^{2+}/\text{Na}^+$), fluspirilene (L-type), HA-1077 2HC1(1-(5 isoquinolinyl sulphonyl) homo piperazine.HCl), isradipine, loperamide HC1, manoalide (Ca^{2+} release inhibitor), nicardipine HC1 (L-type), nifedipine (L-type), niguldipine HC1 (L-type), nimodipine (L-type), nitrendipine (L-type), pimozide (L- and T- type), ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HC1 (L-type), methoxy-verapamil HC1 (L-type), YS-035 HC1 (L-type)N[2(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethaneamine HC1) and AV blockers.

7. (Amended) [A] The method [as claimed in] of claim 6, wherin the AV blocker is adenosine.

8. (Amended) [A] The method [as claimed in] of claim 1 [or 2], wherein the adenosine receptor agonist is selected from N^6 -cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro- N^6 -cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N^6 -(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

Claims 9- 43 are cancelled.

44. (New) The method of claim 3, wherein the adenosine receptor agonist is selected from N^6 -cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro- N^6 -cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N^6 -(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

45. (New) The method of claim 4, wherein the adenosine receptor agonist is selected from N^6 -cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro- N^6 -cyclopentyladenosine

(CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

46. (New) The method of claim 5, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

47. (New) The method of claim 6, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

48. (New) The method of claim 7, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

49. (New) The method of claim 8, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine

(CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

50. (New) The method of claim 44, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

51. (New) The method of claim 45, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

52. (New) The method of claim 46, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

53. (New) The method of claim 47, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine

(CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

54. (New) The method of claim 48, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

55. (New) The method of claim 49, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

56. (New) The method of claim 50, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloradenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

57. (New) The method of claim 1, wherein the local anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mipivacaine and Class 1B antiarrhythmic agents.

58. (New) The method of claim 51, wherein the class 1B antiarrhythmic agent is lignocaine.

59. (New) The method of claim 1, wherein active ingredients (i) and (ii) are administered together with a pharmaceutically acceptable carrier, diluent, adjuvant or excipient.

60. (New) The method of claim 53, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient is a buffer having a pH of about 6 to about 9.

61. (New) The method of claim 54, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient is a buffer having a pH of about 6 to about 9.

62. (New) The method of claim 54, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient has low concentrations of potassium.

63. (New) The method of claim 62, wherein the concentration of potassium is up to about 10mM.

64. (New) The method of claim 57, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl)]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-y1]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexladenosine (CHA).

65. (New) The method of claim 60, wherein the buffer is Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Fremes solution, Hartmanns solution or Ringers-Lactate.

66. (New) The method of claim 59, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient has low concentrations of magnesium.

67. (New) The method of claim 66, wherein the concentration of magnesium is up to about

2.5 mM.

68. (New) The method of claim 1, wherein the active ingredients (i) and (ii) are administered together with another medicament.

69. (New) The method of claim 68, wherein the medicament is dipyridamole or a clot-busting drug.

70. (New) The method of claim 69, wherein the clot-busting drug is streptokinase.

71. (New) The method of claim 1, wherein the subject is a neonate/infant.

72. (New) The method of claim 4, wherein the administration in cardiovascular applications is achieved by mixing the active ingredients with the blood of the subject or a subject having a similar blood type.

73. (New) The method of claim 1, wherein the administration in cardiovascular applications is achieved by mixing the active ingredients with the blood of the subject or a subject having a similar blood type.

74. (New) The method of claim 1, wherein arrest is achieved by either continuous or intermittent delivery.

75. (New) The method of claim 1, wherein the arrest occurs at temperatures of about 15°C to about 37°C.

76. (New) A method for arresting, protecting or preserving an organ comprising adding a composition which includes effective amounts of (i) potassium channel opener or agonist or an adenosine receptor agonist and (ii) a local anaesthetic for use in arresting, protecting or preserving an organ.

77. (New) A pharmaceutical or veterinary composition comprising effective amounts of (i) a

potassium channel opener or agonist or an adenosine receptor agonist and (ii) a local anaesthetic.

78. (New) A composition as claimed in claim 77, wherein the potassium channel opener or agonist is selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy5(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benimidazol-one), amlodipine, Bay K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HC1 (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIIC (Q-type), cyproheptadine HC1, dantrolene sodium (Ca^{2+} release inhibitor), diltiazem HC1 (L-type), filodipine, flunarizine HC1 ($\text{Ca}^{2+}/\text{Na}^+$), fluspirilene (L-type), HA-1077 2HC1(1-(5 isoquinolinyl sulphonyl) homo piperazine.HC1), isradipine, loperamide HC1, manoalide (Ca^{2+} release inhibitor), nicardipine HC1 (L-type), nifedipine (L-type), niguldipine HC1 (L-type), nimodipine (L-type), nitrendipine (L-type), pimozone (L- and T- type), ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HC1 (L-type), methoxy-verapamil HC1 (L-type), YS-035 HC1 (L-type)N[2(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethaneamine HC1) and AV blockers.

79. (New) The composition of claim 77, wherein the adenosine receptor agonist is selected from N^6 -cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro- N^6 -cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a, 2b, 3b, 4a(S^{*})]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579, N^6 -(R)-phenylisopropyladenosine (R-PLA), amnophenylethyladenosine 9APNEA) and cyclohexyladenosine (CHA).

80. (New) The composition of claim 77, wherein the local anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mipivacaine and Class 1B antiarrhythmic agents.

81. (New) The composition of claim 77, wherein the local anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mipivacaine and Class 1B antiarrhythmic agents.

82. (New) The composition of claim 77, wherein the composition is a cardioplegic or

cardioprotectant composition.

83. (New) The composition of claim 77, wherein active ingredients (i) and (ii) are administered together with a pharmaceutically acceptable carrier, diluent, adjuvant or excipient.

84. (New) The composition of claim 83, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient, is a buffer having a pH of about 6 to about 9.

85. (New) The composition of claim 83, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient, has low concentrations of potassium.

86. (New) The composition of claim 85, wherein the concentration of potassium is up to about 10mM.

87. (New) The composition of claim 84, wherein the buffer is Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Fremes solution, Hartmanns solution or Ringers-Lactate.

88. (New) The composition of claim 84, wherein the pharmaceutically acceptable carrier, diluent, adjuvant or excipient has low concentrations of magnesium.

89. (New) The composition of claim 88, wherein the concentration of magnesium is up to about 2. 5mM.

90. (New) The composition of claims 78 wherein the active ingredients (i) and (ii) are administered together with another medicament.

91. (New) The composition of claim 90, wherein the medicament is dipyridamole or a clot-busting drug.

92. (New) The composition of claim 91, wherein the clot-busting drug is streptokinase.

93. (New) The composition of claim 78, wherein the AV blocker is adenosine.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20591-0000
www.uspto.gov

| U.S. APPLICATION NUMBER NO | FIRST NAMED APPLICANT | ATTY. DOCKET NO |
|----------------------------|-----------------------|-----------------|
| 09/937,181 | Geoffrey P Dobson | FREE001 |

Carol M. LaSalle
 Bozicevic Fiel & Francis
 200 Middlefield Road
 Suite 200
 Menlo Park, CA 94025

RECEIVED

DEC 04 2001

Bozicevic, Field & Francis

INTERNATIONAL APPLICATION NO

PCT/AU00/00226

| IA. FILING DATE | PRIORITY DATE |
|-----------------|---------------|
| 03/22/2000 | 03/23/1999 |

CONFIRMATION NO. 6148
371 FORMALITIES LETTER



OC000000007128603

Date Mailed: 11/29/2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Copy of IPE Report
- Copy of the International Application
- Copy of the International Search Report
- Request for Immediate Examination

(B) 12/05/01
 DOCKETED
 MP 01/29/2002
 LD 06/29/2002

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- \$65 Surcharge for providing the oath or declaration later than the appropriate 30 months months from the priority date (37 CFR 1.492(e)) is required.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Additionally the following defects have been observed:

- Additional claim fees of \$27 as a small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$92 for a Small Entity:

- **\$65** Late oath or declaration Surcharge.
- Total additional claim fee(s) for this application is \$27
 - **\$27** for **26** total claims over 20.

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

DARRELL C COTTMAN

Telephone: (703) 305-3693

PART 1 - ATTORNEY/APPLICANT COPY

| U.S. APPLICATION NUMBER NO. | INTERNATIONAL APPLICATION NO. | ATTY. DOCKET NO |
|-----------------------------|-------------------------------|-----------------|
| 09/937,181 | PCT/AU00/00226 | FREE001 |

15/parts.

WO 00/56145

PCT/AU00/00226

1

ORGAN ARREST, PROTECTION AND PRESERVATION

The present invention relates to a method and pharmaceutical or veterinary composition for arresting, protecting and/or preserving organs, in particular the heart during open-heart surgery, cardiovascular diagnosis or therapeutic intervention.

There are over 20,000 open-heart surgery operations each year in Australia, over 800,000 in the United States and about 1,000,000 in Europe. Of those requiring open-heart surgery, about 1.2% are neonates/infants primarily as a consequence of congenital heart disease.

The heart may be arrested for up to 3 hours during open-heart surgery. High potassium cardioplegia (in excess of 15-20 mM) has been the basis of myocardial arrest and protection for over 40 years. Currently the majority of solutions used contain high potassium including the widely used St Thomas No. 2 Hospital Solution which generally contains 110 mM NaCl, 16 mM KCl, 16 mM MgCl₂, 1.2 mM CaCl₂ and 10 mM NaHCO₃ and has a pH of about 7.8. High potassium solutions usually lead to a membrane depolarisation from about -80 to -50mV. Notwithstanding hyperkalemic solutions providing acceptable clinical outcomes, recent evidence suggests that progressive potassium induced depolarisation leads to ionic and metabolic imbalances that may be linked to myocardial stunning, ventricular arrhythmias, ischaemic injury, endothelial cell swelling, microvascular damage, cell death and loss of pump function during the reperfusion period. Infant hearts are even more prone to damage with cardioplegic arrest from high potassium than adult hearts. The major ion imbalances postulated are linked to an increased sodium influx which in turn activates the Na⁺/Ca²⁺ exchangers leading to a rise in intracellular Ca²⁺. Compensatory activation of Na⁺ and Ca²⁺ ion pumps then occur, which activate anaerobic metabolism to replenish ATP with a concomitant increase in tissue lactate and fall in tissue pH. Free radical generation and oxidative stress have also been implicated in potassium arrest and partially reversed by the administration of antioxidants. In some cases, high potassium induced

ischaemia has been reported to have damaged smooth muscle and endothelial function.

In an attempt to minimise ischaemic damage during cardioplegic arrest, an increasing number of experimental studies have employed potassium channel openers instead of high potassium. Cardioprotection using nicorandil, apricalim or pinacidil is believed to be linked to the opening of the potassium channel which leads to a hyperpolarised state, a shortening of the action potential and decreasing Ca^{2+} influx into the cell. One shortfall however is that the heart takes the same time or longer to recover with no improvement in function than with high potassium cardioplegic solutions. Another limitation is that pinacidil requires a carrier due to its low solubility in aqueous solutions. The carrier routinely used is dimethyl sulphoxide (DMSO) which is controversial when used in animal or human therapy.

Most investigators, including those who advocate using potassium channel openers, believe that as soon as blood flow is halted and the arrest solution administered, ischaemia occurs and progressively increases with time. To reduce the likelihood of damage, we sought a cardioplegic solution that would place the heart in a reversible hypometabolic state analogous to the tissues of a hibernating turtle, a hummingbird in torpor or an aestivating desert frog. When these animals drop their metabolic rate (some by over 90%), their tissues do not become progressively ischaemic but remain in a down-regulated steady state where supply and demand are matched. An ideal cardioplegic solution should produce a readily reversible, rapid electrochemical arrest with minimal tissue ischaemia. The heart should accumulate low tissue lactate, utilise little glycogen, show minimal changes in high-energy phosphates, cytosolic redox (NAD/NADH) and the bioenergetic phosphorylation (ATP/ADP Pi) ratio and free energy of ATP. There should be little or no change in cytosolic pH or free magnesium, minimal water shifts between the intracellular and extracellular phases, and no major ultrastructural damage to organelles such as the mitochondria. The ideal cardioplegic solution should produce 100% functional recovery with no ventricular arrhythmia, cytosolic calcium overload

or other pump abnormalities. There is no cardioplegic solution currently available which fulfils all these requirements. We have now found that the heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine.

- 5 The action of adenosine is controversial. Adenosine has been shown to increase coronary blood flow, hyperpolarise the cell membrane and act as a preconditioning agent via the ATP-sensitive potassium channel and adenosine related pathways including adenosine receptors notably the A1 receptor. Adenosine is also known to improve myocardial recovery as an adjunct to high
- 10 potassium cardioplegia. Furthermore, adenosine can be used as a pretreatment (whether or not it is present in the arresting solution) to reduce lethal injury. In one study, adenosine was shown to rival potassium arrest solutions and more recently in blood cardioplegia, it prevented post-ischaemic dysfunction in ischaemically injured hearts. Adenosine is sometimes added as an adjunct to
- 15 potassium cardioplegia.

Lignocaine is a local anaesthetic which blocks sodium fast channels and has antiarrhythmic properties by reducing the magnitude of inward sodium current. The accompanying shortening of the action potential is thought to directly reduce calcium entry into the cell via Ca^{2+} selective channels and

20 $\text{Na}^+/\text{Ca}^{2+}$ exchange. Recent reports also implicate lignocaine with the scavenging of free radicals such as hydroxyl and singlet oxygen in the heart during reperfusion. Associated with this scavenging function, lignocaine may also inhibit phospholipase activity and minimise membrane degradation during ischaemia. Lignocaine has also been shown to have a myocardial protective

25 effect and in one study was found to be superior to high potassium solutions. However, our experiments show that lignocaine alone at 0.5, 1.0 and 1.5 mM gave highly variable functional recoveries using the isolated working rat heart.

According to one aspect of the present invention there is provided a method for arresting, protecting and/or preserving an organ which includes

30 administering effective amounts of (i) a potassium channel opener or agonist

and/or an adenosine receptor agonist and (ii) a local anaesthetic to a subject in need thereof.

According to another aspect of the present invention there is provided the use of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic in the manufacture of a medicament for arresting, protecting and/or preserving an organ.

The present invention also provides (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic for use in arresting, protecting and/or preserving an organ.

According to a further aspect of the present invention there is provided a pharmaceutical or veterinary composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.

While the present invention is particularly advantageous in arresting, protecting and/or preserving an organ while it is intact in the body of the subject, it will be appreciated that it may also be used to arrest, protect and/or preserve isolated organs.

Thus, the present invention still further provides a method for arresting, protecting and/or preserving an organ which includes adding a composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic to the organ.

The term “organ” is used herein in its broadest sense to refer to any methods of exposing the organ to the composition of the present invention, for example, bathing, perfusing or pumping via various routes.

The term “organ” is used herein in its broadest sense and refers to any part of the body exercising a specific function including tissues and cells or parts thereof, for example, cell lines or organelle preparations. Other examples include circulatory organs such as the heart, respiratory organs such as the lungs, urinary organs such as the kidneys or bladder, digestive organs such as the stomach, liver, pancreas or spleen; reproductive organs such as the scrotum, testis, ovaries or uterus, neurological organs such as the brain, germ cells such

as spermatozoa or ovum and somatic cells such as skin cells, heart cells i.e., myocytes, nerve cells, brain cells or kidney cells.

The method of the present invention is particularly useful in arresting, protecting and/or preserving the heart during open-heart surgery including heart transplants. Other applications include reducing heart damage before, during or following cardiovascular intervention which may include a heart attack, angioplasty or angiography. For example, the composition could be administered to subjects who have suffered or are developing a heart attack and used at the time of administration of blood clot-busting drugs such as streptokinase. As the clot is dissolved, the presence of the composition may protect the heart from further injury such as reperfusion injury. The composition may be particularly effective as a cardioprotectant in those portions of the heart that have been starved of normal flow, nutrients and/or oxygen for different periods of time. For example, the composition may be used to treat heart ischaemia which could be pre-existing or induced by cardiovascular intervention.

Thus, the present invention also provides a cardioplegic or cardioprotectant composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.

The potassium channel openers or agonists may be selected from nicorandil, diazoxide, minoxidil, pinacidil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy5-(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benimidazol-one), amlodipine, Bay K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HCl (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIIC (Q-type), cyproheptadine HCl, dantrolene sodium (Ca^{2+} release inhibitor), diltiazem HCl (L-type), filodipine, flunarizine HCl ($\text{Ca}^{2+}/\text{Na}^+$), fluspirilene (L-type), HA-1077 2HCl(1-(5 isoquinolinyl sulphonyl) homo piperazine.HCl), isradipine, loperamide HCl, manoalide (Ca^{2+} release

- inhibitor), nicardipine HCl (L-type), nifedipine (L-type), nifuglipine HCl (L-type), nimodipine (L-type), nitrendipine (L-type), pimozide (L- and T-type), ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HCl (L-type), methoxy-verapamil HCl (L-type), YS-035 HCl (L-type)N[2(3,4-
5 dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethaneamine HCl) and AV blockers such as verapamil and adenosine. It will be appreciated that this list includes calcium antagonists as potassium channel openers are indirect calcium antagonists.

Adenosine is particularly preferred as it is capable of opening the potassium channel, hyperpolarising the cell, depressing metabolic function, possibly protecting endothelial cells, enhancing preconditioning of tissue and protecting from ischaemia or damage. Adenosine is also an indirect calcium antagonist, vasodilator, antiarrhythmic, antiadrenergic, free radical scavenger, arresting agent, anti-inflammatory agent (attenuates neutrophil activation), metabolic agent and possible nitric oxide donor.

In a preferred embodiment, the present invention provides a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of adenosine and a local anaesthetic to a subject in need thereof.

- Suitable adenosine receptor agonists include N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-ribofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexyladenosine (CHA).

- The local anaesthetic can be selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mepivacaine and Class 1B antiarrhythmic agents such as

lignocaine or derivatives thereof, for example, QX-314. Lignocaine is preferred as it is capable of acting as a local anaesthetic probably by blocking sodium fast channels, depressing metabolic function, lowering free cytosolic calcium, protecting against enzyme release from cells, possibly protecting endothelial cells and protecting against myofilament damage. Lignocaine is also a free radical scavenger and an antiarrhythmic.

As lignocaine acts by blocking sodium fast channels, it will be appreciated that other sodium channel blockers could be used instead of or in combination with the local anaesthetic in the method and composition of the present invention. Examples of suitable sodium channel blockers include venoms such as tetrodotoxin.

Thus, in a particularly preferred embodiment there is provided a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of adenosine and lignocaine to a subject in need thereof.

In another preferred embodiment there is provided a pharmaceutical or veterinary composition which includes effective amounts of adenosine and lignocaine.

For ease of reference, the "potassium channel opener or agonist and/or adenosine receptor agonist" and the "local anaesthetic" will hereinafter be referred to as the "active ingredients".

The method of the present invention involves the administration of effective amounts of the active ingredients for a time and under conditions sufficient for the organ to be arrested, protected and/or preserved. The active ingredients may be administered separately, sequentially or simultaneously and in a single dose or series of doses.

The subject may be a human or an animal such as a livestock animal (e.g. sheep, cow or horse), laboratory test animal (e.g. mouse, rabbit or guinea pig) or a companion animal (e.g. dog or cat), particularly an animal of economic importance.

It will be appreciated that the amounts of active ingredients present in the composition will depend on the nature of the subject, the type of organ being arrested, protected and/or preserved and the proposed application. In the case of a human subject requiring heart arrest during open-heart surgery, the concentration of adenosine is preferably about 0.001 to about 20mM, more preferably about 0.01 to about 10mM, most preferably about 0.05 to about 5mM and the concentration of lignocaine is preferably about 0.001 to about 20mM, more preferably about 0.01 to about 10mM, most preferably about 0.05 to about 5mM. In the case of a human subject requiring treatment before, during or following a heart attack or cardiovascular intervention, the preferred concentrations of adenosine and lignocaine are set out in the table below.

| Site of Injection | Type/Units | Adenosine | |
|-------------------|-------------|---------------|----------------|
| Lignocaine | | | |
| Intravenous | Infusion | 1. 0.001-10 | 1. 0.0001-20 |
| | mg/min/kg | 2. 0.01-5 | 2. 0.01-10 |
| | | 3. 0.01-1 | 3. 0.5-3 |
| Intravenous | Bolus | 1. 0.0001-100 | 1. 0.001-1000 |
| | mg/kg | 2. 0.001-10 | 2. 0.01-100 |
| Intracoronary | Infusion | 1. 0.0001-100 | 1. 0.005-50 |
| | mg/min | 2. 0.001-1 | 2. 0.005-5 |
| | (per heart) | 3. 0.01-0.5 | 3. 0.05-2.5 |
| Intracoronary | Bolus | 1. 0.001-1000 | 1. 0.01-10,000 |
| | μg | 2. 0.1-100 | 2. 1-1000 |
| | (per heart) | 3. 1-20 | 3. 10-200 |

1 = preferably

15 2 = more preferably

3 = most preferably

The active ingredients may be administered by any suitable route including oral, implant, rectal, inhalation or insufflation (through the mouth or nose), topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intrasternal and intradermal). Preferably, administration in open-heart surgery or cardiovascular intervention applications will be achieved by mixing the active ingredients with the blood of the subject or subjects having a similar blood type. The active ingredients then enter the coronary circulation generally via the aorta. Arrest may also be achieved by either continuous or intermittent delivery. For example, heart arrest may occur by either continuous or intermittent perfusion retrograde through the aorta in the Langendorff mode. However, it will be appreciated that the preferred route will vary with the condition and age of the subject and the chosen active ingredients.

The composition of the present invention is highly beneficial at about 15°C to about 37°C, preferably about 20°C to about 37°C, where longer arrest times using St Thomas No. 2 solution can only be achieved when the temperature is lowered, for example, down to about 4°C.

While it is possible for one or both of the active ingredients to be administered alone, it is preferable to administer one or both of them together with one or more pharmaceutically acceptable carriers, diluents adjuvants and/or excipients. Each carrier, diluent, adjuvant and/or excipient must be pharmaceutically "acceptable" in the sense of being compatible with the other ingredients of the composition and not injurious to the subject. The compositions may conveniently be presented in unit dosage form and may be prepared by methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. Preferably, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers, diluents, adjuvants and/or excipients.

The present invention also extends to a pharmaceutical or veterinary composition which includes the active ingredients and a pharmaceutically or veterinarily acceptable carrier, diluent, adjuvant and/or excipient.

- Compositions of the present invention suitable for oral administration 5 may be presented as discrete units such as capsules, sachets or tablets each containing a predetermined amount of the active ingredients; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredients may also be presented as a bolus, electuary or paste.
- 10 A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. pre-gelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose), fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate), lubricants (e.g. magnesium stearate, talc or silica), inert diluent, preservative, disintegrant (e.g. magnesium stearate, talc or silica), inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose), surface-active or dispersing 15 agents. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
- 20 Liquid preparations for administration prior to arresting, protecting and/or preserving the organ may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by means with pharmaceutically acceptable additives
- 25
- 30

such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid); and energy sources (e.g. carbohydrates such as glucose, fats such as palmitate or amino acid).

Compositions suitable for topical administration in the mouth include lozenges comprising the active ingredients in a flavoured basis, usually sucrose and acacia or tragacanth gum; pastilles comprising the active ingredients in an inert basis such as gelatin and glycerin, or sucrose and acacia gum; and mouthwashes comprising the active ingredients in a suitable liquid carrier.

For topical application for the skin, the active ingredients may be in the form of a cream, ointment, jelly, solution or suspension.

For topical application to the eye, the active ingredients may be in the form of a solution or suspension in a suitable sterile aqueous or non-aqueous vehicle. Additives, for instance buffers, preservatives including bactericidal and fungicidal agents, such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorohexidine and thickening agents such as hydromellose may also be included.

The active ingredients may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the active ingredients may be formulated with suitable polymeric or hydrophobic materials (e.g. as an emulsion in an acceptable oil or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Compositions for rectal administration may be presented as a suppository or retention enema with a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the active ingredients. Such excipients include cocoa butter or a salicylate.

SEARCHED
INDEXED
COPIED
FILED

For intranasal and pulmonary administration, the active ingredients may be formulated as solutions or suspensions for administration via a suitable metered or unit dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.

5 Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

10 Compositions suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended subject; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.

15 The compositions may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described

20 When the composition is for veterinary use it may be prepared, for example, by methods that are conventional in the art. Examples of such veterinary compositions include those adapted for:

- (a) oral administration, external application, for example drenches (e.g. aqueous or non-aqueous solutions or suspensions); tablets or boluses; powders, granules or pellets for admixture with feedstuffs; pastes for application to the tongue;
- (b) parenteral administration for example by subcutaneous, intramuscular or intravenous injection, e.g. as a sterile solution or suspension; or (when appropriate) by intramammary injection where a suspension or solution is introduced into the udder via the teat;

- (c) topical application, e.g. as a cream, ointment or spray applied to the skin; or
- (d) intravaginally, e.g. as a pessary, cream or foam.

It should be understood that in addition to the ingredients particularly mentioned above, the compositions of this invention may include other agents conventional in the art having regard to the type of composition in question, for example, those suitable for oral administration may include such further agents as binders, sweeteners, thickeners, flavouring agents, disintegrating agents, coating agents, preservatives, lubricants and/or time delay agents.

10 Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharin. Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar. Suitable flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring. Suitable coating agents include polymers or copolymers of acrylic acid and/or methacrylic acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten. Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite. Suitable lubricants include magnesium stearate, steric acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate.

15 A preferred pharmaceutically acceptable carrier is a buffer having a pH of about 6 to about 9, preferably about 7, more preferably about 7.4 and/or low concentrations of potassium, for example, up to about 10mM, more preferably about 2 to about 8 mM, most preferably about 4 to about 6mM. Suitable buffers include Helsel-Hensleit which generally contains 10mM glucose, 117 mM NaCl, 5.9 mM KCl, 25 mM NaHCO₃, 1.2 mM NaH₂PO₄, 1.12 mM CaCl₂ (free Ca²⁺=1.07mM) and 0.512 mM MgCl₂ (free Mg²⁺=0.5mM), St. Thomas No. 2 solution, Tyrodes solution which generally contains 10mM glucose, 126 mM NaCl, 5.4 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 0.33 mM NaH₂PO₄ and 10 mM HEPES (N-[2-hydroxyethyl]piperazine-N'-[2-ethane sulphonic acid], Femes solution, Hartmanns solution which generally contains 129 NaCl, 5 mM KCl, 2

mM CaCl₂ and 29 mM lactate and Ringers-Lactate. One advantage of using low potassium is that it renders the present composition less injurious to the subject, in particular pediatric subjects such as neonates/infants. High potassium has been linked to an accumulation of calcium which may be
5 associated with irregular heart beats during recovery, heart damage and cell swelling. Neonates/infants are even more susceptible than adults to high potassium damage during cardiac arrest. After surgery for defects a neonate/infant's heart may not return to normal for many days, sometimes requiring intensive therapy or life support. It is also advantageous to use
10 carriers having low concentrations of magnesium, such as, for example up to about 2.5mM, but it will be appreciated that high concentrations of magnesium, for example up to about 20mM, can be used if desired without substantially effecting the activity of the composition.

In a further preferred embodiment the present invention provides a
15 pharmaceutical or veterinary composition which includes adenosine, lignocaine and a pharmaceutically acceptable carrier which contains up to about 10mM potassium.

In a still further preferred embodiment, the present invention provides a pharmaceutical or veterinary composition which includes adenosine, lignocaine
20 and Krebs-Henseleit buffer.

The composition may also advantageously be presented in the form of a kit in which the active ingredients are held separately for separate, sequential or simultaneous administration.

It will be appreciated that the composition of the present invention may
25 also include and/or be used in combination with known medicaments depending on the proposed application. For instance, medicaments which substantially prevent the breakdown of adenosine in the blood such as nucleoside transport inhibitors, for example, dipyridamole could be used as additives in the composition of the present invention. The half life of adenosine in the blood is
30 about 10 seconds so the presence of a medicament to substantially prevent its breakdown will maximise the effect of the composition of the present invention.

Dipyridamole could advantageously be included in concentrations from about 0.1nM to about 10 mM and has major advantages with respect to cardioprotection. Dipyridamole may supplement the actions of adenosine by inhibiting adenosine transport which increases vasodilation. This could be
5 particularly important when the composition is administered intermittently.

Other examples of medicaments include clot-busting drugs such as streptokinase. As discussed earlier, the composition could be administered at the time of administration of streptokinase in subjects who have suffered or are developing a heart attack.

10 The invention will now be described with reference to the following examples. These examples are not to be construed as limiting in any way.

In the example, reference will be made to the accompanying drawings in which:

15 Figure 1 is a graph of aortic flow vs time comparing hearts arrested using 100 μ M adenosine and 0.5 mM lignocaine in Krebs-Henseleit and St. Thomas Hospital No. 2 solution;

Figure 2 is six graphs showing heart rate, systolic pressure, aortic flow, coronary flow, MV02 and rate pressure product recovery from 30 mins intermittent ischaemia;

20 Figure 3 is six graphs showing heart rate, systolic pressure, aortic flow, coronary flow, MV02 and rate pressure product recovery from 2hrs intermittent ischaemia;

Figure 4 is six graphs showing heart rate, systolic pressure, aortic flow, coronary flow, MV02 and rate pressure product recovery from 4hrs intermittent ischaemia;

25 Figure 5 is a bar graph providing a summary of the results of Figures 2 to 4;

Figure 6 is six graphs showing heart rate, systolic pressure, aortic flow, coronary flow, MV02 and rate pressure product recovery from 2hrs of
30 intermittent ischaemia using neonate rat hearts;

Figure 7 is four graphs showing 20min ischaemia in rat heart *in vivo* following coronary artery ligation with no adenosine-lignocaine infusion;

Figure 8 is four graphs showing 20min ischaemia in rat heart *in vivo* following coronary artery ligation when infused with adenosine (6.3mg/ml) and lignocaine (12.6mg/ml) at 1ml/hour/300g rat;

Figure 9 is a graph showing 30min ischaemia in rat heart *in vivo* following coronary artery ligation when infused with adenosine (6.3mg/ml) and lignocaine (12.6mg/ml) at 1ml/hour/300g rat;

Figure 10 is four graphs showing 20min ischaemia in rat heart *in vivo* following coronary artery ligation when infused with adenosine (3.15mg/ml) and lignocaine (12.6mg/ml) at 1ml/hour/300g rat;

Figure 11 is four graphs showing 30min ischaemia in rat heart *in vivo* following coronary artery ligation when infused with adenosine (1.6mg/ml) and lignocaine (12.6mg/ml) at 1ml/hour/300g rat;

Figure 12 is a graph showing 30min ischaemia in rat heart *in vivo* following coronary artery ligation when infused with adenosine (1.6mg/ml) and lignocaine (12.6mg/ml) at 1ml/hour/300g rat;

Figure 13 is two graphs showing the change in ATP and PCr versus time of ischaemia during a heart attack *in vivo* with and without the presence of AL;

Figure 14 is two graphs showing the change in lactate and myocardial pH versus time of ischaemia during a heart attack *in vivo* with and without the presence of AL; and

Figure 15 is two graphs showing the change in glycogen and rate pressure product versus time of ischaemia during a heart attack *in vivo* with and without the presence of AL.

In the examples, "AL" refers to compositions containing adenosine and lignocaine.

EXAMPLE 1

This example compares the effects of adenosine (100 μ M) cardioplegia with hyperkalemic St. Thomas Hospital No. 2 solution (16 mM K⁺) on

functional recovery after a period of global ischaemia using continuous perfusion.

- Hearts from male 450g Sprague-Dawley rats ($n=19$) were perfused for 30 minutes in the working mode (preload 7.5 mmHg; afterload 100 mmHg) with
- 5 Krebs-Henseleit pH 7.4 buffer at 37°C. Hearts were then arrested in a retrograde mode at a constant pressure of 70 mmHg with either (i) a solution containing 100 μ M adenosine and 0.5 mM lignocaine in filtered Krebs-Henseleit (10 mM glucose, pH 7.6 – 7.8 @ 37°C) ($n=11$) or (ii) St. Thomas No 2 solution (0.2 micron filter) ($n=8$). Following either 30 minutes or 4hrs of
- 10 arrest, the hearts were switched back to normal antegrade perfusion with Krebs-Henseleit pH 7.4 @ 37°C. Heart rate, coronary flow, aortic flow, aortic pressure and oxygen consumption were monitored. Statistical significance was assessed using a Student t-Test.

15 Results

- Hearts arrested for 30 minutes using adenosine cardioplegia achieved quiescence in half the time compared to St. Thomas No. 2 solution (30 vs 77 seconds, $p<0.0001$). During arrest under a constant perfusion pressure, coronary blood flow was 30% greater using adenosine cardioplegia ($p<0.05$).
- 20 Faster recoveries were found in AL hearts in aortic pressure, aortic flow and cardiac output during reperfusion. After 5 min into reperfusion, the heart rate, aortic pressures, aortic flow, coronary flow, cardiac output and O₂ consumption were higher in the AL hearts (Table 1). Higher aortic flows were also found at 15, 25 and 35 min against a perfusion head of 100 mmHg (Figure 1).

Table 1

Comparison between adenosine and lignocaine cardioplegia and St Thomas No 2 Hospital solution after 30 min Normothermic Continuous Arrest in the working rat heart (37°C)

| Parameter | Adenosine and lignocaine (n=11) | | | Thomas No 2 Solution (n=12) | | |
|--|--|-------------|---------|--------------------------------|------------|---------|
| | Time to electromechanical arrest (sec) | 30 ± 2 sec | Control | 5 min | Recovery | Control |
| Heart (bpm) | 292 ± 9 | 213 ± 8 | 73% | 285 ± 14 | 150 ± 35 | 53% |
| Systolic pressure (mmHg) | 122 ± 3 | 126 ± 4 | 103% | 126 ± 3 | 88 ± 14 | 70%* |
| Diastolic Pressure (mmHg) | 76 ± 1 | 74 ± 1.3 | 97% | 78.5 ± 1.2 | 59 ± 8.5 | 75% |
| Aortic flow (ml/min) | 35.6 ± 3 | 24 ± 4 | 67% | 31.5 ± 4.1 | 9.96 ± 2.8 | 32%* |
| Coronary flow (ml/min) | 16.4 ± 0.7 | 13.6 ± 0.9 | 83% | 17.4 ± 0.74 | 10 ± 1.9 | 57% |
| Cardiac Output (ml/min) | 52 ± 3 | 37.2 ± 4.7 | 72% | 50 ± 4 | 20 ± 4.5 | 40%* |
| O ₂ consumption (μmol/min/g wt) | 6.97 ± 0.28 | 5.39 ± 0.38 | 77% | 7.28 ± 0.30 | 4.14 ± 0.5 | 57% |
| wt) | | | | | | |

Control values are taken 5 min prior to the 30 min arrest protocol. * Significant P<0.05

In terms of functional parameters, 100 μ M adenosine and 0.5 mM lignocaine cardioplegia lead to shorter arrest times and an enhanced recovery profile compared to the St. Thomas Hospital No. 2 solution.

The results for hearts arrest for 4hrs are shown in Table 2 below.

Table 2

Comparison of functional Recovery of S-D Rat Hearts After 30min Continuous Cardioplegia With Adenosine/Lignocaine Cardioplegia or St Thomas Hospital Solution No. 2

| n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Coronary Flow (ml/min) | Aortic Flow (ml/min) | Cardiac Output (ml/min) | Stable Perfusion Period | |
|----------------------------------|------------------|--------------------------|------------------------|----------------------|-------------------------|-------------------------|--|
| | | | | | | MV02 (nmol/min/g) | Arrest |
| Adenosine + Lignocaine | 7 | 292.18 ± 8.82 | 122.38 ± 3.58 | 16.44 ± 1.07 | 35.66 ± 3.33 | 52 ± 2.73 | 6.97 ± 0.28 |
| Cardioplegia | % | 100 | 100 | 100 | 100 | 100 | 30 min Cardioplegic Arrest with Constant Perfusion Delivered at 70mmHg |
| St Thomas Hospital Solution No 2 | 10 | 2.85 | 128.08 | 17.4 | 31.53 | 48.93 | 100 |
| | % | 100 | 100 | 100 | 100 | 100 | 100 |

Table 2 cont.

| After 5min Reperfusion | | | | | | |
|------------------------|----|---------------------|-----------------------------|---------------------------|-------------------------|--------------------------------|
| | n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Coronary Flow (ml/min) | Aortic Flow (ml/min) | Cardiac Output (μmol/min/g) |
| Adenosine | 7 | 212.91 | 126.09 | 13.6 | 23.64 | 37.24 |
| + Lignocaine | | ± 7.62 | ± 4.15 | ± 0.92 | ± 4.09 | 5.39 |
| Cardioplegia | % | 73 | 103 | 83 | 66 | ± 0.38 |
| St Thomas | 10 | 150.36 | 88.08 | 10.09 | 9.96 | 72 |
| Hospital | | ± 34.45 | ± 14.21 | ± 1.93 | ± 2.83 | 77 |
| Solution No. 2 | % | 53 | 70 | 57 | 32 | 4.14 |
| | | | | | 40 | ± 0.5 |
| | | | | | | 57 |

Table 2 cont.

| After 15min Reperfusion | | | | | | |
|-------------------------|----|---------------------|-----------------------------|---------------------------|-------------------------|----------------------------|
| | n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Coronary Flow (ml/min) | Aortic Flow (ml/min) | Cardiac Output (ml/min) |
| Adenosine | 7 | 262.18 | 114.9† | 12.55 | 25.07 | 37.82 |
| + Lignocaine | | ± 10.36 | ± 4.18 | ± 1.03 | ± 3.08 | ± 3.89 |
| Cardioplegia | % | 90 | 94 | 76 | 71 | 72 |
| St Thomas Hospital | 10 | 257.09 | 118.82 | 15.05 | 16.18 | 31.24 |
| Solution No. 2 | % | 90 | 94 | 86 | 51 | 64 |
| | | | | | | 84 |

Table 2 cont.

| | After 5min Reperfusion | | | | | | |
|--------------------|------------------------|---------------------|-----------------------------|---------------------------|-------------------------|----------------------------|----------------------|
| | n | Heart Rate (ppm) | Systolic Pressure (mmHg) | Coronary Flow (ml/min) | Aortic Flow (ml/min) | Cardiac Output (ml/min) | MV02 (μmol/min/g) |
| Adenosine | 7 | 253.54 | 118.4 | 14.08 | 30.52 | 44.8 | 8.06 |
| + Lignocaine | | ± 28.47 | ± 3.58 | ± 0.75 | ± 2.73 | ± 3 | ± 0.31 |
| Cardioplegia % | 87 | 97 | 86 | 86 | 86 | 86 | 87 |
| St Thomas Hospital | 10 | 266.91 | 118.09 | 15.05 | 23.11 | 38.16 | 6.6 |
| Solution No. 2 % | 94 | 15.16 | ± 3.43 | ± 1.04 | ± 3.94 | ± 4.47 | ± 0.48 |
| | | 94 | 86 | 73 | 78 | 78 | 91 |

Table 2 cont.

| After 35min Reperfusion | | | | | | | |
|---------------------------|----|---------------------|-----------------------------|---------------------------|-------------------------|----------------------------|----------------------------------|
| | n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Coronary Flow (ml/min) | Aortic Flow (ml/min) | Cardiac Output (ml/min) | MVO ₂ (μmol/min/g) |
| Adenosine | 7 | 283.83 | 118.88 | 14.2 | 32.13 | 46.33 | 6.54 |
| + Lignocaine | | ± 11.74 | ± 4.62 | ± 0.68 | ± 2.94 | ± 3.43 | ± 0.09 |
| Cardioplegia % | 97 | 97 | 88 | 90 | 89 | 94 | 23 |
| St Thomas Hospital | 10 | 271.27 | 120.45 | 15.38 | 25.35 | 40.74 | 6.74 |
| Solution No. 2 % | 96 | ± 14.04 | ± 3.11 | ± 1.37 | ± 4.03 | ± 4.4 | ± 0.48 |
| | | | 96 | 88 | 80 | 89 | 96 |

EXAMPLE 2

Adult rat hearts (350g) were prepared using the method described in Example 2 and then subjected to intermittent perfusion as discussed below.

Intermittent retrograde perfusion was performed under a constant pressure head of 70mmHg after hearts were switched back from the working mode to the Lagendorff mode. After stabilisation, the hearts were arrested using 50ml of either adenosine plus lignocaine cardioplegia or St Thomas Hospital No 2 solution. The aorta was then cross-clamped and the heart left to sit arrested for 20min (except in 30 min intermittent arrest protocol), after which the clamp was released and 2min of arrest solution delivered from a pressure head of 70 mmHg. The clamp was then replaced and this procedure continued for up to 30mins, 2hrs and 4hrs at 37°C.

Intermittent cardioplegic delivery is the method commonly used clinically in contrast to continuous perfusion in Example 1. During Intermittent arrest, the aorta of the subject is clamped and the arrest solution administered. After a few minutes, the heart is arrested and cardioplegia delivery stopped. The heart remains motionless to permit surgery. The arrest solution is administered again every 30 min for few minutes to maintain the heart in the arrested state to preserve and protect the heart muscle. Between these times, the heart muscle slowly becomes ischaemic indicated by the production of lactate and fall in muscle pH. For this reason, intermittent perfusion delivery is often called intermittent ischaemic arrest. The results are shown in Tables 3 to 7 below and Figures 2 to 5.

25 30min Ischaemic Arrest At 37°C

Table 3 and Figure 2 show that A-L arrests in half the time of St Thomas solution 21s (n=7) vs 53s (n=10). All hearts returned function to the same level following reperfusion (no significant difference between groups).

Table 3

Characteristics of Adult Heart 30min Intermittent Arrest* Achieved by Adenosine/Lignocaine Cardioplegia and St Thomas Hospital Solution No. 2
***(2min cardioplegia pulse after 15 min periods of aortic clamping)**

| | Adenosine/Lignocaine | St Thomas | P |
|--|-----------------------|-----------------------------------|--------|
| | Cardioplegia (n=7) | Hospital Solution No. 2 (n=10) | |
| Arrest Time (s) | 21.43 ± 3.92 | 52.78 ± 5.65 | p<0.01 |
| Time to First Contraction Following Reperfusion (s) | 147.14 ± 14.95 | 133.67 ± 31.44 | ns |
| Time to Recover 100mmHg | 302.14 ± 21.87 | 309.44 ± 30.15 | ns |

Table 4

Comparison of functional Recovery of Rat Hearts after 30min Intermittent Ischaemia* With Adenosine/Lignocaine Cardioplegia or St Thomas Hospital Solution No 2

| | | Stable Perfusion Period | | | | | | | |
|----------------------------------|-------|--------------------------|----------------------|------------------------|-------------------------|-----------------------|-------------------------------|--------------------|--|
| n | Heart | Systolic Pressure (mmHg) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RP Product (mmHg/min) | MVO ₂ (μmol/min/g) | Arrest | |
| Adenosine | 7 | 245.38 | 128.23 | 34.33 | 21.64 | 58.29 | 31504 | 6.31 | |
| + Lignocaine | | ± 11.01 | ± 2.83 | ± 3.64 | ± 2.02 | ± 4.63 | ± 1651 | ± 0.65 | |
| Cardioplegia | | | | | | | | 30min Ischaemia | |
| St Thomas Hospital Solution No 2 | 10 | 276.74 | 123.64 | 32.78 | 19.38 | 55.36 | 34090 | 5.97 | |
| | | ± 11.87 | ± 1.30 | ± 2.09 | ± 1.62 | ± 2.59 | ± 1111 | ± 0.56 | |
| | | | | 100 | 100 | 100 | 100 | 100 | |
| | | | | | | | | Delivered at 15min | |

Table 4 cont.

| After 5min Reperfusion | | | | | | | |
|------------------------|------------------|--------------------------|----------------------|------------------------|-------------------------|---|-------------------------------|
| n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RP Prox icd (mmHg/cm ² .min) | MVO ₂ (umol/min/g) |
| Adenosine | 7 | 180.48 | 132.79 | 22.06 | *22.15 | 47.59 | 24074 |
| + Lignocaine | | ± 26.83 | ± 6.65 | ± 4.48 | ± 2.20 | ± 2.70 | 6.81 |
| Cardioplegia | 74 | 104 | 64 | 102 | 82 | ± 3330 | ± 0.97 |
| St Thomas Hospital | 10 | 135.94 | 81.82 | 19.04 | *13.48 | 34.61 | 76 |
| | | ± 32.71 | ± 15.94 | ± 4.69 | ± 2.47 | 23281 | 108 |
| Solution No 2 | 49 | | 58 | 70 | ± 6.96 | ± 4069 | 5.02 |
| | | | | | 63 | 68 | ± 0.79 |
| | | | | | 84 | | |

*Statistically Significant Difference Using Students TTEST ($p<0.05$)

Table 4 cont.

| | After 15min Reperfusion | | | | | | |
|--------------------|-------------------------|--------------------------|----------------------|------------------------|-------------------------|-----------------------|-------------------------------|
| n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RP Product (mmHg/min) | MVO ₂ (μmol/min/g) |
| Adenosine | 7 | 225.31 | 126.17 | 29.21 | 17.14 | 48.99 | 28228 |
| + Lignocaine | | ± 19.17 | ± 2.88 | ± 3.20 | ± 1.81 | ± 3.76 | 5.03 |
| Cardioplegia | 92 | 98 | 85 | 79 | 84 | ± 2015 | ± 0.49 |
| St Thomas Hospital | 10 | 255.88 | 121.56 | 24.84 | 17.00 | 45.07 | 31131 |
| Solution No 2 | 92 | 98 | 76 | 88 | 81 | ± 1267 | 5.41 |
| | | | | | 91 | | ± 0.53 |
| | | | | | 91 | | |

Table 4 cont.

| | After 30min Reperfusion | | | | | | | |
|-----------------------|-------------------------|---------------------|--------------------------------|-------------------------|------------------------------|-------------------------------|--------------------------|----------------------------|
| | n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RP Product (mmHg/min) | MVQ2 (μ mol/min/g) |
| Adenosine | 7 | 236.94 | 124.84 | 29.60 | 16.49 | 49.09 | 29403 | 5.42 |
| + Lignocaine | ± 13.75 | ± 2.61 | ± 2.83 | ± 1.51 | ± 1.95 | ± 1231 | ± 0.70 | |
| Cardioplegia | 97 | 97 | 86 | 76 | 84 | 93 | 86 | |
| St Thomas Hospital | 10 | 255.17 | 122.16 | 22.26 | 17.08 | 42.41 | 31154 | 5.26 |
| Solution No 2 | 92 | ± 12.29 | ± 1.62 | ± 3.32 | ± 1.20 | ± 3.28 | ± 1464 | ± 0.38 |
| | | 99 | 68 | 88 | 77 | 91 | 88 | |

Table 4 cont.

| After 60min Reperfusion | | | | | | | |
|-------------------------|---------------------|--------------------------------|-------------------------|------------------------------|-------------------------------|--------------------------|----------------------|
| n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RP Product (mmHg/min) | MV02 (μmol/min/g) |
| Adenosine | 7 | 244.97 | 119.80 | 22.42 | 15.52 | 41.53 | 29269 |
| + Lignocaine | ± 11.48 | ± 2.95 | ± 3.48 | ± 0.49 | ± 2.78 | ± 1240 | 5.25 ± 0.55 |
| Cardioplegia | 100 | 93 | 65 | 72 | 71 | 93 | 83 |
| St Thomas Hospital | 10 | 258.16 | 117.57 | 17.01 | 15.46 | 35.89 | 30392 |
| Solution No 2 | 93 | 13.88 | ± 1.68 | ± 3.08 | ± 1.21 | ± 3.46 | 5.08 ± 0.33 |
| | | 95 | 52 | 80 | 65 | 89 | 85 |

30

PCT/AU00/00226

WO 00/56145

2hr Ischaemic Arrest At 37°C

Table 5 and Figure 3 show that A-L arrests in half the time of St Thomas solution 33s (n=7) vs 81s (n=8). 4 out of 8 hearts arrested with St Thomas did not recover. All A-L hearts survived (n=7). St Thomas hearts which recovered (n=4) had 50-90% aortic flow, 70-120% heart rate and 90-100% systolic pressure. A-L hearts recovered 80% aortic flow, 95% heart rate and 95-100% systolic pressure.

10 **Table 5**

Characteristics of Adult Rat Heart 2hr Ischaemic Arrest* Achieved by Adenosine/Lignocaine Cardioplegia and St Thomas Hospital Solution No. 2

*(2min Cardioplegia pulse repeated after 20 min of aortic clamping)

| | n | Adenosine/ Lignocaine Cardioplegia | n | St Thomas Hospital Solution No. 2 | p |
|--|---|--|---|---|--------|
| Arrest Time(s) | 7 | 33 \pm 5 | 8 | 81 \pm 8 | 0.0003 |
| Time to First Contraction following Reperfusion(s) | 7 | 360 \pm 19 | 4 | 260 \pm 95 | NS |
| Time to Recover 100mmHg and Achieve Aortic flow(s) | 7 | 541 \pm 46 | 4 | 2400 \pm 3261 | NS |
| Percentage of Hearts to Survive Reperfusion | | 100 | | 50 | |

4hr Ischaemic Arrest At 37°C

Tables 6 and 7 and Figure 4 show A-L arrests in half the time of St Thomas solution (26s (n=9) vs 78s (n=7)). 6 out of 7 hearts arrested with St Thomas did not recover. All A-L hearts survived (n=9). The single St Thomas heart which recovered had 40% aortic flow, 80% heart rate and 90% systolic pressure. A-L hearts recovered 70% aortic flow, 90% heart rate and 95-100% systolic pressure.

10 Table 6

Characteristics of Adult Rat Heart 4hr Ischaemic Arrest* Achieved by Adenosine/Lignocaine Cardioplegia and St Thomas Hospital Solution No. 2

***(2min cardioplegia pulse repeated after 20 min of aortic clamping)**

| | Adenosine/ Lignocaine Cardioplegia | St Thomas Hospital Solution No. 2 | p |
|--|--|---|---------|
| Arrest Time(s) | 26.44 \pm 2.77 (n=9) | 77.86 \pm 10 (n=7) | <0.001 |
| Time to First Contraction following Reperfusion(s) | 401.67 28.48 (n=9) | 390.00 (n=1) | |
| Time to Recover 100mmHg and Achieve Aortic flow(s) | 549.22 40.68 (n=9) | 480.00 (n=1) | |
| Percentage of Hearts to Survive Reperfusion | 100 (n=9) | 14 (n=1) | <0.0001 |

Table 7

Comparison of Function Recovery of Rat Hearts After 4hr Intermittent Ischaemic Arrest with Adenosine/Lignocaine Cardioplegia or St Thomas Hospital Solution No. 2

| | n | Stable Perfusion Period | | | | | | MV02 ($\mu\text{mol}/\text{min/g}$) | Arrest |
|------------------------|-----|-------------------------|--------------------------|----------------------|------------------------|-------------------------|-----------------------|--|---|
| | | Heart Rate (bpm) | Systolic Pressure (mmHg) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RP Product (mmHg/min) | | |
| Adenosine + Lignocaine | 9 | 275.33 ± 12.91 | 118.44 ± 3.50 | 36.47 ± 1.65 | 16.28 ± 1.03 | 53.88 ± 1.73 | 32338 ± 1084 | 6.71 ± 0.45 | 4hr Ischaemic Arrest with 2min Cardioplegia |
| Cardioplegia | | | | | | | | | |
| St Thomas Hospital | 7 | 259.21 ± 12.84 | 121.57 ± 2.42 | 41.23 ± 4.18 | 16.03 ± 1.26 | 57.26 ± 5.30 | 31508 ± 1672 | 7.64 ± 0.24 | Delivered Every 20min |
| Solution No. 2 (n=1) | 270 | 117.00 | 51 | 19.8 | 70.8 | 315900 | 7.28 | | |

Table 7 cont.

| After 15min Reperfusion | | | | | | |
|-------------------------|---------------------|--------------------------------|-------------------------|------------------------------|-------------------------------|--------------------------|
| n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RP Product (mmHg/min) |
| Adenosine | 9 | 229.89 | 110.89 | 19.81 | 13.92 | 36.49 |
| + Lignocaine | ± 16.10 | ± 1.86 | ± 3.56 | ± 1.53 | ± 4.13 | 25327 |
| Cardioplegia | % 83 | 94 | 54 | 86 | 68 | 5.94 |
| St Thomas | 1 | 220.00 | 100 | 18.60 | 16.20 | 36.40 |
| Hospital | % 81 | 85 | 36 | 82 | 51 | 22000 |
| Solution No. 2 | | | | | 70 | 5.303 |
| | | | | | 73 | ± 0.69 |
| | | | | | | 89 |

Table 7 cont.

| | After 30min Reperfusion | | | | | | | |
|----------------|-------------------------|---------------------|--------------------------------|-------------------------|------------------------------|-------------------------------|---------------------------|----------------------------------|
| | n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RPP Product (mmHg/min) | MVO ₂ (umol/min/g) |
| Adenosine | 9 | 239.444 | 113.00 | 24.62 | 11.53 | 39.44 | 26684 | 4.946 |
| + Lignocaine | | ± 18.7165 | ± 3.07 | ± 2.917 | ± 1.001 | ± 4.259 | ± 1669 | ± 0.443 |
| Cardioplegia | % 87 | 95 | 68 | 71 | 73 | 83 | 74 | |
| St Thomas | 1 | 220 | 105.00 | 16.8 | 20.4 | 39.2 | 23100 | 5.303 |
| Hospital | % 81 | 90 | 33 | 103 | 55 | 73 | 73 | |
| Solution No. 2 | | | | | | | | |

35

35

Table 7 cont.

| After 60min Reperfusion | | | | | | | |
|-------------------------|------|---------------------|--------------------------------|-------------------------|------------------------------|-------------------------------|---|
| | n | Heart Rate (bpm) | Systolic Pressure (mmHg) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RP Product (mmHg/min) k. VO2 (μ mJ/min/g) |
| Adenosine | 9 | 249.22 | 111.89 | 25.58 | 11.39 | 40.63 | 27570 5.04 |
| + Lignocaine | | ± 17.19 | ± 3.29 | ± 3.26 | ± 1.32 | ± 4.72 | ± 1577 ± 0.49 |
| Cardioplegia | % 91 | 94 | 70 | 70 | 70 | 75 | 85 75 |
| St Thomas Hospital | 1 | 250.00 | 102.00 | 14.40 | 18.00 | 34.40 | 25500 6.29 |
| Solution No. 2 | | % 93 | 87 | 28 | 91 | 49 | 81 86 |

Figure 5 is a summary of the results of Figures 2 to 4 which shows hearts arrested with AL solution all survived after 30 min ischaemic intermittent arrest (n=7), 2 hrs intermittent arrest (n=7) and 4 hrs of intermittent arrest (n=9). In contrast, while all hearts arrested with St Thomas solution survived after 30 min (n=10), only 50% (4 out of 8 tested) and 14% survived (1 out of 7) tested. In addition, two hearts have been arrested with AL successfully for 6 hrs (Figure 5).

Figures 2 to 4 show the functional properties (heart rate, systolic pressure, aortic flow, coronary flow, oxygen consumption and rate-pressure product) during 60 min after 0.5 hr arrest (Figure 2) 2hr arrest (Figure 3) and 4 hrs arrest (Figure 4). In all cases, hearts arrested with AL solution had higher functional recovery parameters. After 0.5 hr arrest, these differences were not significant except for aortic flow recover in hearts receiving AL arrest solution. Aortic flow against a pressure head of 70 mmHg recovered to 90% of control values at 30 min compared to 65% in St Thomas hearts. After 2 hr intermittent ischaemic arrest the differences in functional recover are more striking. In AL arrested hearts, heart rate and systolic pressure recovered to nearly 100% of control values whereas St. Thomas hearts only recovered 40-50%. Aortic flow, coronary flow, oxygen consumption and rate-pressure product recovered 80% and above the controls in AL hearts and only 20-40% in St Thomas hearts. After 4 hr arrest the differences were even grater with only 1 out of 7 St Thomas hearts recovering. All AL hearts recovered after 4 hr arrest with similar recovery functional profiles described above for 2 hr. It can be concluded that AL arrest provides superior protection during 2 and 4 hr arrest and recovery in adult hearts.

EXAMPLE 3

Neonatal/infant rat hearts (using 50-70g 20 day old rats) were prepared using the intermittent perfusion technique for 2hr at 37°C described in Example 2 except the pressure head of delivery and afterload was reduced to 50mmHg. The results shown in Tables 8 and 9 below and Figure 6 show that A-L arrests

in a third of the time of St Thomas solution 19s (n=7) vs 66s (n=7). 3 out of 7 hearts arrest with St Thomas did not recover. All A-L hearts survived (n=7) with 80% aortic flow. The St Thomas hearts which recovered averaged 80% aortic flow rate, but this was extremely variable.

- 5 All neonatal/infant hearts arrested with AL solution recovered after 2 hr intermittent ischaemic arrest. Only 4 out o 7 hearts arrested with St Thomas solution recovered after 2 hr intermittent ischaemic arrest. In AL arrested hearts, heart rate and systolic pressure recovered to 90-100% of control values wherein St Thomas' hearts there was only 50-60% recovery. Aortic flow,
10 coronary flow and rate-pressure product recovered to 80% and above the controls in AL hearts and only about 50% in St Thomas hearts. Oxygen consumption in the AL hearts was 70-85% of controls and about 60% for the hearts arrested with St Thomas solution. It can be concluded that AL arrest provides superior protection during 2 hr arrest and recover in neonatal/infant
15 hearts.

Table 8

Characteristics of Neonatal Immature Rat Heart Arrest* Achieved by Adenosine/Lignocaine Cardioplegia and St Thomas Hospital No. 2

*(2 min Cardioplegia pulse repeated after 20 min of aortic clamping).

Reperfusion afterload of 50 mmHg.

| | Adenosine/ Lignocaine | St Thomas Hospital Solution No. 2 | p |
|---|--------------------------|--------------------------------------|-------|
| Arrest Time(s) | 18.57 $\pm 3.72(7)$ | 65.71* $\pm 12.71(7)$ | <0.05 |
| Time to First Contraction Following Reperfusion(s) | 23.83 $\pm 3.03(7)$ | 55.75* $\pm 12.97(4)$ | <0.05 |
| Time to Recover 50mmHg Aortic flow(s) | 165 $\pm 29.48(7)$ | 270 $\pm 83.5(4)$ | ns |
| Percentage of Hearts to Survive Reperfusion | 100(7) | 57*(4) | <0.05 |
| Arrhythmia Occurrence (%) | 14(7) | 25(4) | ns |

* Denotes Statistical Significance p<0.05 using Students t-test

Table 9 cont.

| After 60min Reperfusion | | | | | | |
|-------------------------|---|---------------------|-------------------------|---------------------------|----------------------------|--------------------------|
| | n | Heart Rate (bpm) | Aortic Flow (ml/min) | Coronary Flow (ml/min) | Cardiac Output (ml/min) | RP Product (mmHg/min) |
| Adenosine | 7 | 242.78 | 6 | 3.75 | 13.05 | 13272 |
| + Lignocaine | | ± 30.35 | ± 1.66 | ± 0.57 | ± 1.55 | 4.13 |
| Cardioplegia | | | | | ± 2.643 | ± 0.62 |
| St Thomas Hospital | 4 | 234.48 | 3.88 | 3.58 | 9.68 | 13910 |
| Solution No 2 | | ± 40.16 | ± 1.41 | ± 0.92 | ± 1.50 | 4.02 |
| | | | | | ± 3262 | ± 0.75 |

EXAMPLE 4

Table 10 below shows that adenosine and lignocaine are effective in 1-2 day old neonatal pig heart cardioplegia. (2 hours of 2min pulses of cardioplegia administered between 20min periods of aortic clamping).

Table 10

| <i>n</i> | Arrest Time (s) | Heart Rate Recovery (After 2hr Arrest*) |
|----------|--------------------|--|
| 1 | 8 | 75% |

EXAMPLE 5

Male Wistar rats (250g) were housed in a temperature and light-controlled room. Food and water were provided freely until the day before the experiment when the food was withheld and the rats were fasted overnight. The rats were anaesthetised with an intraperitoneal injection of pentobarbital (60mg kg^{-1}). Under anaesthesia, the rats were implanted with cannulas in the femoral vein and artery for adenosine and lignocaine (AL) administration and blood pressure measurement, respectively. A tracheotomy was performed and the rats were artificially ventilated with room air at 60 to 70 breaths/min. The chests of the rats were cut open and the left anterior descending (LAD) coronary artery located. A piece of suture was placed underneath LAD. After a 20min baseline period, LAD of the group of experimental rats were ligated for 30min and blood pressure and heart rate monitored. After 30 min of ischaemia, the ligature was released and the heart reperfused for 20 min. In the control rats, no AL was administered as shown in Figure 7. In the AL infusion 3 rats were used at three different doses of adenosine:

(1) 6.3 mg/ml adenosine + 12.6 mg/ml lignocaine infused at 1 ml/hr/300 g rat as shown in Figures 8 and 9;

- (2) 3.15 mg/ml adenosine + 12.6 mg/ml lignocaine infused at 1 ml/hr/300 g rat as shown in Figure 10; and
(3) 1.6 mg/ml adenosine + 12.6 mg/ml lignocaine infused at 1 ml/hr/300 g rat as shown in Figures 11 and 12.

5 Compared to rats with 30 min ischaemia (no AL infusion) it was found that AL protected the heart in a dose dependent manner with the greatest protection occurring at the higher doses. As the dose of adenosine was halved, the protection was progressively lost. However, even in the worse case, the function of the heart was significantly better than with no AL alone. All hearts
10 in rats receiving AL recovered in rate and pressure.

Summary of Adenosine and lignocaine during a Heart Attack *in vivo*

During a 30 min heart attack or myocardial infarction (MI) in the rat model, Figure 7 shows that at 10 min blood pressure approaches zero and the animal would be considered close to death. After 10 min, the heart recovers and blood pressure increases and is highly erratic from the ischaemic insult. This recovery is probably due to the recruitment of collateral circulation. In contrast, when a solution of adenosine and lignocaine is infused into the rat 5 min before occluding the coronary artery, no such fall in blood pressure is seen at 10 min (Figure 8). Where the animal without receiving AL solution nearly died at 10 min, in the presence of AL solution the heart lowers its rate of contraction and misses only a few beats. Noteworthy, there was no irregular beating of the heart at 20 min of ischaemia. All hearts recovered to full function after AL infusion was stopped (Figure 9). It can be concluded that the heart in the presence of AL solution was dramatically protected against a profound ischaemic insult elicited by occluding the coronary artery. The protective effect of the AL solution on the heart was related to the dose of adenosine. If the amount of adenosine was halved but the amount of lignocaine remained constant, only at 10 min and 20 is seen (Figure 10). If the amount of adenosine was halved again, the protection was reduced further. In all cases

however, AL infused rats fully recovered haemodynamic function based on blood pressure and heart rate (Figure 12).

- Two groups of rats undergoing a heart attack with and without a solution of AL were placed in a nuclear magnetic resonance (NMR) spectrometer and the metabolic data is shown in Figures 13 to 15. NMR non-invasively measures the changes in adenosine-triphosphate (ATP), phosphocreatine (PCr) and pH during 30 min of coronary artery occlusion. In a separate experiment on the bench, hearts were freeze-clamped at liquid nitrogen temperatures and glycogen and lactate were measured using routine enzymatic methods on neutralised tissue acid-extracts using a spectrophotometer. Major significant differences ($P<0.05$) were seen in the hearts receiving AL solution during coronary artery occlusion. ATP remained between 90-100% of the control values in AL hearts compared to 60% in hearts receiving no AL (Figure 13). The same was shown for the high-energy phosphate store PCr, although greater percentage falls were shown in hearts with no AL (down to as low as 20% of pre-occlusion values) (Figure 14). In hearts receiving AL over the ischaemic period lactate, an end-product of anaerobic metabolism, increased 5-fold whereas lactate in hearts without AL increased over 20-fold (Figure 15). This was also supported by measuring the myocardial cell pH; greater decreases in pH (more acid) are seen in hearts not receiving AL solution. Noteworthy, in the first 10 min the pH fell only slight in AL hearts indicating that the myocardial cells in the presence of AL were more aerobic supported by the lower tissue lactate levels. The fuel glycogen was used in similar amounts by hearts with and without AL in the first 10 min but remained at about 60-70% of the pre-occlusion values in AL hearts compared to ischaemic hearts alone. It can be concluded from the metabolic data that coronary-occluded hearts receiving AL remained more aerobic than those hearts not receiving AL. Glycogen was a major source of fuel for each heart but the AL hearts preferentially regenerated their ATP from mitochondrial oxidative phosphorylation not from lactate production. This is wholly consistent with the functional data discussed above from changes in blood pressure and heart rate.

EXAMPLE 6

Arrest solutions were made with 200 μ M and 50 μ M of the local anaesthetics prilocaine, procaine and mepivacaine in Krebs-Henseleit having 10mM glucose at pH7.4. The results shown in Table 11 below are for 30min constant perfusion of cardioplegia at 70mmHg.

Table 11

| | Adenosine + PRILOCAINE | Adenosine + PROCAINE | Adenosine + MEPIVACAIN |
|----------------------|---------------------------|-------------------------|---------------------------|
| ARREST TIME | 13s | 21s | 10.5s |
| 1 st BEAT | 1:13 | 1:45 | 0:36 |
| AORTIC FLOW | 3:12 | 3:35 | 3:40 |
| RECOVERY | | | |
| 5min AF% | 67% | 58% | 39% |

EXAMPLE 7

Arrest solutions were made with pinacidil dissolved in 0.05% dimethylsulfoxide (DMSO) (200 μ M) the local anaesthetics prilocaine, procaine, mepivacaine and lignocaine in Krebs-Henseleit solution. As shown in Table 12 below, pinacidil was found to be not as effective as adenosine.

Table 12

| | Pinacidil + PRILOCAINE | Pinacidil + PROCAINE | Pinacidil + MEPIVACAIN | Pinacidil + LIGNOCAIN |
|----------------------|---------------------------|-------------------------|---------------------------|--------------------------|
| Arrest Time | 1:28 | 4:22s | 0:41 | |
| 1 ST Beat | 2:15 | 1:20 | 0:56 | 1:49 |
| Aortic Flow | 8:10 | 4:50 | 6:55 | 2:30 |
| Recovery | | | | 4:45 |
| 5min AF% | 0% | 25% | 0% | 70% |
| 15min AF% | 38% | 57% | 36% | 71% |

EXAMPLE 8

The addition of the ATP-potassium channel blocker, glibenclamide (20 μ M) and adenosine and lignocaine, delayed arrest times more than threefold from 26 sec (AL) to 76-120 sec (ALG) (n=2). Furthermore the slower recovery times and lower aortic flow (42-53%) in the presence of glibenclamide shows the importance of opening the KATP channels as a mode of arrest and protection afforded by AL. It can be concluded from these results that the ATP-potassium channel is an important target eliciting the arrest response from adenosine and lignocaine.

10

Table 13

| | A/L + 20 μ M Glibenclamide (n=2) | A/L Alone (n=5) |
|----------------------|---|--------------------|
| Arrest Time | 76-120s | 26.s |
| 1 st Beat | 2:45-2:55 (min:s) | 1min:37s |
| Aortic Flow | 5:00-7:30 (min:s) | 3min:51s |
| Recovery Time | | |
| 5min AF% | 42-53% | 84% |

Claims

1. A method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof.
2. A method as claimed in claim 1, wherein the organ is either intact in the body of the subject or isolated.
3. A method as claimed in claim 1 or 2, wherein the organ is a circulatory 10 organ, respiratory organ, urinary organ, digestive organ, reproductive organ, neurological organ or somatic cell.
4. A method as claimed in claim 3, wherein the circulatory organ is a heart.
5. A method as claimed in claim 4, which is used to arrest, protect and/or preserve the heart during open-heart surgery, reduce heart damage before, 15 during or following cardiovascular intervention or protect those portions of the heart that have been starved of normal flow, nutrients and/or oxygen.
6. A method as claimed in any one of claims 1 to 5, wherein the potassium channel opener or agonist is selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benimidazol-one), amlodipine, Bay K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HCl (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIIC (Q-type), cyroheptadine HCl, dantrolene sodium (Ca^{2+} release inhibitor), diltiazem HCl (L-type), filodipine, flunarizine HCl (Ca^{2+}/Na^+), fluspirilene (L-type), HA-1077 2HCl(1-(5 isoquinoliny1 sulphonyl) homo piperazine.HCl), isradipine, loperamide HCl, manoalide (Ca^{2+} release inhibitor), nicardipine HCl (L-type), nifedipine (L-type), niguldipine HCl (L-type), nimodipine (L-type), nitrendipine (L-type), pimozone (L- and T- type), 20 ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HCl (L-type), methoxy-verapamil HCl (L-type), YS-035 HCl (L-type)N[2(3,4-
- 25
- 30

dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethaneamine HCl) and AV blockers.

7. A method as claimed in claim 6, wherein the AV blocker is adenosine.
8. A method as claimed in any one of claims 1 to 7, wherein the adenosine receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl)]ethyladenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robosugar]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexyladenosine (CHA).
9. A method as claimed in any one of claims 1 to 8, wherein the local anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mepivacaine and Class 1B antiarrhythmic agents.
10. A method as claimed in claim 9, wherein the class 1B antiarrhythmic agent is lignocaine.
11. A method as claimed in any one of claims 1 to 10, wherein active ingredients (i) and (ii) are administered together with a pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient.
12. A method as claimed in claim 11, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient is a buffer having a pH of about 6 to about 9.
13. A method as claimed in claim 11 or 12, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient has low concentrations of potassium.
14. A method as claimed in claim 13, wherein the concentration of potassium is up to about 10mM.

15. A method as claimed in any one of claims 12 to 14, wherein the buffer is Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Femes solution, Hartmanns solution or Ringers-Lactate.
- 5 16. A method as claimed in any one of claims 11 to 15, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient has low concentrations of magnesium.
17. A method as claimed in claim 16, wherein the concentration of magnesium is up to about 2.5mM.
- 10 18. A method as claimed in any one of claims 1 to 17, wherein the active ingredients (i) and (ii) are administered together with another medicament.
19. A method as claimed in claim 18, wherein the medicament is dipyridamole or a clot-busting drug.
20. A method as claimed in claim 19, wherein the clot-busting drug is streptokinase.
- 15 21. A method as claimed in any one of claims 1 to 20, wherein the subject is a neonate/infant.
22. A method as claimed in any one of claims 4 to 21, wherein the administration in cardiovascular applications is achieved by mixing the active ingredients with the blood of the subject and/or a subject having a similar blood type.
- 20 23. A method as claimed in any one of claims 1 to 22, wherein arrest is achieved by either continuous or intermittent delivery.
24. A method as claimed in any one of claims 1 to 23, wherein the arrest occurs at temperatures of about 15°C to about 37°C.
- 25 25. Use of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic in the manufacture of a medicament for arresting, protecting and/or preserving an organ.
26. A (i) potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic for use in arresting, protecting and/or preserving an organ.
- 30

27. A method for arresting, protecting and/or preserving an organ which comprises adding a composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic to the organ.
- 5 28. A pharmaceutical or veterinary composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.
29. A composition as claimed in claim 28, wherein the potassium channel opener or agonist is selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benimidazol-one), amlodipine, Bay K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HCl (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIIC (Q-type), cyproheptadine HCl, dantrolene sodium (Ca^{2+} release inhibitor), diltiazem HCl (L-type), filodipine, flunarizine HCl ($\text{Ca}^{2+}/\text{Na}^+$), fluspirilene (L-type), HA-1077 2HCl(1-(5 isoquinoliny1 sulphonyl) homo piperazine.HCl), isradipine, loperamide HCl, manoalide (Ca^{2+} release inhibitor), nicardipine HCl (L-type), nifedipine (L-type), niguldipine HCl (L-type), nimodipine (L-type), nitrendipine (L-type), pimozone (L- and T- type), ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HCl (L-type), methoxy-verapamil HCl (L-type), YS-035 HCl (L-type)N[2(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethaneamine HCl) and AV blockers.
- 10 15 20 25 30. A composition as claimed in claim 29, wherein the AV blocker is adenosine.
31. A composition as claimed in claims 28 to 30, wherein the adenosine receptor agonist is selected from N^6 -cyclopentyladenosine (CPA), N -ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl)ethyl]adenosine, 2-chloro- N^6 -

- cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-methylpropyl)amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexyladenosine (CHA).
- 5 32. A composition as claimed in claims 28 to 31, wherein the local anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mepivacaine and Class 1B antiarrhythmic agents.
- 10 33. A composition as claimed in any one of claims 28 to 32 wherein the composition is a cardioplegic or cardioprotectant composition.
34. A composition as claimed in any one of claims 28 to 33, wherein active ingredients (i) and (ii) are administered together with a pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient.
- 15 35. A composition as claimed in claim 34, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient, is a buffer having a pH of about 6 to about 9.
36. A composition as claimed in claim 34 or 35, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient has low concentrations of potassium.
- 20 37. A composition as claimed in claim 36, wherein the concentration of potassium is up to about 10mM.
38. A composition as claimed in any one of claims 35 to 37, wherein the buffer is Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Femes solution, Hartmanns solution or Ringers-Lactate.
- 25 39. A composition as claimed in any one of claims 34 to 38, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient has low concentrations of magnesium.
40. A composition as claimed in claim 39, wherein the concentration of magnesium is up to about 2.5mM.

41. A composition as claimed in any one of claims 29 to 40, wherein the active ingredients (i) and (ii) are administered together with another medicament.
42. A composition as claimed in claim 41, wherein the medicament is
5 dipyridamole or a clot-busting drug.
- 43 A composition as claimed in claim 42, wherein the clot-busting drug is streptokinase.

20070707T074630

09/937181

WO 00/56145

PCT/AU00/00226

1/15




Figure 1

09/937181

WO 00/56145

PCT/AU00/00226

2/15




Figure 2

09/937181

WO 00/56145

PCT/AU00/00226

3/15




Figure 3

09/937181

WO 00/56145

PCT/AU00/00226

4/15




Figure 4

09/937181

WO 00/56145

PCT/AU00/00226

5/15




Figure 5

09/937181

WO 00/56145

PCT/AU00/00226

6/15






Figure 6

FIG. 7



8 / 15


FIG. 8



9/15


FIG. 9

Reperfusion Without A/L 10min after
Removal of Ligature



10/15


FIG. 10



AMENDED SHEET
IPEA/AU


11 / 15

FIG. 11



12/15

FIG. 12



COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: Organ arrest, protection and preservation

the specification of which (check only one item below):

- is attached hereto.
 was filed as United States application

Serial No. _____

on _____

and was amended

on _____ (if applicable).

- was filed as PCT international application

Number PCT/AU00/00226

on 23 March 2000

and was amended under PCT Article 19

on 27 February 2001 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, '1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, '119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

| COUNTRY (if PCT, indicate "PCT") | APPLICATION NUMBER | DATE OF FILING (day, month, year) | PRIORITY CLAIMED UNDER 35 USC 119 |
|-------------------------------------|--------------------|--------------------------------------|---|
| Australia | PP9414 | 23 March 1999 | <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO |
| Australia | PQ4199 | 23 November 1999 | <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO |

Combined Declaration For Patent Application and Power of Attorney (Continued)
 (Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET
 NUMBER

I hereby claim the benefit under Title 35, United States Code, '120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, '112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, '1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

| U.S. APPLICATIONS | | STATUS (Check one) | | |
|-------------------------|------------------|--------------------|---------|-----------|
| U.S. APPLICATION NUMBER | U.S. FILING DATE | PATENTED | PENDING | ABANDONED |
| | | | | |
| | | | | |
| | | | | |

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (*List name and registration number*)

Karl Bozicevic, Reg. No. 28,807
 Bret E. Field, Reg. No. 37,620
 Paula A. Borden, Reg. No. 42,344
 Alan W. Cannon, Reg. No. 34,977
 Robert Hall, Reg. No. 39,209
 Nicole Verona, Reg. No. 47,153

Carol L. Francis, Reg. No. 36,513
 Pamela J. Sherwood, Reg. No. 36,677
 Cheryl Franke, Reg. No. 44,113
 Carol M. LaSalle, Reg. No. 39,740
 Kathleen Hall, Reg. No. 44,143

Send Correspondence to:

BOZICEVIC, FIELD & FRANCIS LLP

200 Middlefield Road, Suite 200

Menlo Park, CA 94025

Telephone: (650) 327-3400

Faxsimile: (650) 327-3231


Direct Telephone Calls to:
 (name and telephone number)

Name:
 Registration No.
 Telephone: (650) 327-3400

| | | | | |
|-----|-------------------------|--|--|---|
| 201 | FULL NAME OF INVENTOR | FAMILY NAME <u>DOBSON</u> | FIRST GIVEN NAME <u>Geoffrey</u> | SECOND GIVEN NAME <u>Phillip</u> |
| | RESIDENCE & CITIZENSHIP | CITY <u>Wulguru, Queensland 4811</u> | STATE OR FOREIGN COUNTRY <u>Australia</u> | COUNTRY OF CITIZENSHIP <u>AU</u> |
| | POST OFFICE ADDRESS | POST OFFICE ADDRESS <u>14 Dahl Crescent</u> | CITY <u>Wulguru</u> | STATE & ZIP CODE/COUNTRY <u>Queensland 4811, Australia</u> |
| 202 | FULL NAME OF INVENTOR | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME |
| | RESIDENCE & CITIZENSHIP | CITY | STATE OR FOREIGN COUNTRY | COUNTRY OF CITIZENSHIP |
| | POST OFFICE ADDRESS | POST OFFICE ADDRESS | CITY | STATE & ZIP CODE/COUNTRY |
| 203 | FULL NAME OF INVENTOR | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME |
| | RESIDENCE & CITIZENSHIP | CITY | STATE OR FOREIGN COUNTRY | COUNTRY OF CITIZENSHIP |

| | | | |
|---------------------|---------------------|------|--------------------------|
| POST OFFICE ADDRESS | POST OFFICE ADDRESS | CITY | STATE & ZIP CODE/COUNTRY |
|---------------------|---------------------|------|--------------------------|


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

| | | |
|--|---------------------------|---------------------------|
| SIGNATURE OF INVENTOR 201  | SIGNATURE OF INVENTOR 202 | SIGNATURE OF INVENTOR 203 |
| DATE 24 September 2001 | DATE | DATE |

M:\FORMS\COMDEC.WP 5/96

PATENT TRADEMARK OFFICE

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

Page(s) _____ of _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)

** Scanned copy is best available. There are only 12 sheets of drawings.*